ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2025
Efficacy of Omalizumab against Japanese Cedar pollinosis in clinical practice.
Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundJapanese cedar pollinosis (JCP), which affects over 40% of the population and represents a major public health issue in Japan, has various treatment options, but limited clinical reports and high costs necessitate careful patient selection. This study aimed to evaluate the efficacy of omalizumab in treating JCP and identify key considerations for its appropriate clinical application.
methodsWe retrospectively analyzed 42 patients with JCP treated with omalizumab from 2021 to 2024. Treatment response was assessed using a 3-category patient-reported scale across all years. In a 2023-2024 subset (n = 23), quantitative total symptom score (TSS) data were available, allowing effect-size estimation and subgroup analyses.
resultsThe study included 42 patients (30 men, 71.4%) aged 12-80 years (mean, 41.5 ± 17.2 years). Symptom improvement was observed in 38 patients (90%), including marked improvement in 23 (55%). Responders were younger (mean age 39.9 vs. 55.5 years) and had higher total IgE levels (251 vs. 211 IU/mL) than nonresponders. No significant correlation was observed between nasal eosinophil counts and treatment response. In the 2023-2024 subset (n = 23), TSS decreased significantly (mean paired difference - 2.61; p = 0.0010). Subgroup analyses suggested that CRSsNP cases tended to show insufficient improvement, while younger age and higher IgE levels were associated with better response trends.
conclusionsOmalizumab significantly improved symptoms and QOL in patients with JCP. However, its high cost and the risk of nonresponse necessitate careful patient selection. Age and IgE levels may help guide treatment decisions, highlighting the importance of individualized strategies for severe JCP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.